{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:09Z","timestamp":1791260169532,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T00:00:00Z","timestamp":1509753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s13318-017-0445-7","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T01:13:46Z","timestamp":1509758026000},"page":"281-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole"],"prefix":"10.1007","volume":"43","author":[{"given":"Kyle John","family":"Wilby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,4]]},"reference":[{"key":"445_CR1","unstructured":"World Health Organization. The top 10 causes of death. Global Disease Burden. World Health Organization. 2017. \n                        http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/\n                        \n                    . Accessed 14 Sept 2017."},{"key":"445_CR2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1099\/jmm.0.46548-0","volume":"55","author":"DA Enoch","year":"2006","unstructured":"Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55:809\u201318.","journal-title":"J Med Microbiol"},{"key":"445_CR3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/504490","volume":"43","author":"MA Pfaller","year":"2006","unstructured":"Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43:S3\u201314.","journal-title":"Clin Infect Dis"},{"key":"445_CR4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","volume":"35","author":"JM Rybak","year":"2015","unstructured":"Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35:1037\u201351.","journal-title":"Pharmacotherapy"},{"key":"445_CR5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/myc.12517","volume":"59","author":"S Kim","year":"2016","unstructured":"Kim S, Kwon J, Park C, Han S, Yim D, Choi J, et al. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether B-cyclodextrin in haematological patients with renal impairment. Mycoses. 2016;59:644\u201351.","journal-title":"Mycoses"},{"key":"445_CR6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/17512433.2015.1034689","volume":"8","author":"JN Moore","year":"2015","unstructured":"Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015;8:321\u201334.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"445_CR7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","volume":"9","author":"SK Natesan","year":"2016","unstructured":"Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive Aspergillosis and Mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291\u2013300.","journal-title":"Infect Drug Resist"},{"key":"445_CR8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760\u20139.","journal-title":"Lancet"},{"key":"445_CR9","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR III, et al. Isavuconazole treatment for Mucormycosis: a single-arm open-label trial and case\u2013control analysis. Lancet Infect Dis. 2016;16:828\u201337.","journal-title":"Lancet Infect Dis"},{"key":"445_CR10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","volume":"63","author":"GR Thompson III","year":"2016","unstructured":"Thompson GR III, Rendon A, Riberio dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, et al. Isavuconazole treatment of Cryptococcosis and dimorphic mycoses. Clin Infect Dis. 2016;63:356\u201362.","journal-title":"Clin Infect Dis"},{"key":"445_CR11","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.04586-14","volume":"59","author":"J Viljoen","year":"2015","unstructured":"Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother. 2015;59:1671\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR12","doi-asserted-by":"crossref","first-page":"ofx040","DOI":"10.1093\/ofid\/ofx040","volume":"4","author":"SE Jacobs","year":"2017","unstructured":"Jacobs SE, Saez-Lacy D, Wynkoop W, Walsh TJ. Successful treatment of allergic bronchopulmonary aspergillosis with isavuconazole: care report and review of the literature. Open Forum Infect Dis. 2017;4:ofx040.","journal-title":"Open Forum Infect Dis"},{"key":"445_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","volume":"50","author":"A Schmitt-Hoffmann","year":"2006","unstructured":"Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200\u00a0mg) and oral administrations (100, 200, and 400\u00a0mg) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50:279\u201385.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","volume":"50","author":"A Schmitt-Hoffmann","year":"2006","unstructured":"Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50:286\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.376","author":"R Townsend","year":"2017","unstructured":"Townsend R, Kato K, Hale C, Kowalski D, Lademacher C, Yamazaki T, et al. Two phase I, open-label, mass balance studies to determine the pharmacokinetics of 14C-labeled isavuconazonium sulfate in healthy male volunteers. Clin Pharmacol Drug Dev. 2017;. \n                        https:\/\/doi.org\/10.1002\/cpdd.376\n                        \n                    .","journal-title":"Clin Pharmacol Drug Dev"},{"key":"445_CR16","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","volume":"59","author":"OA Cornely","year":"2015","unstructured":"Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59:2078\u201385.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00101-17","volume":"61","author":"LL Kovanda","year":"2017","unstructured":"Kovanda LL, Marty FM, Maertens J, Desai AV, Lademacher C, Engelhardt M, et al. Impact of mucositis on absorption and systemic drug exposure of isavuconazole. Antimicrob Agents Chemother. 2017;61:1\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR18","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","volume":"60","author":"A Desai","year":"2016","unstructured":"Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive injections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60:5483\u201391.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR19","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00514-16","volume":"60","author":"LL Kovanda","year":"2016","unstructured":"Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, Hope WW. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). Antimicrob Agents Chemother. 2016;60:4568\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR20","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.00319-09","volume":"53","author":"A Schmitt-Hoffmann","year":"2009","unstructured":"Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Peterfai E, Edwards DJ, Stoeckel K. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53:4885\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"445_CR21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-017-2213-7","volume":"73","author":"RW Townsend","year":"2017","unstructured":"Townsend RW, Akhtar S, Alcorn H, Berg JK, Kowalski DL, Mujais S, Desai AV. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017;73:669\u201378.","journal-title":"Eur J Clin Pharmacol"},{"key":"445_CR22","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1093\/jac\/dku311","volume":"69","author":"BM Knoll","year":"2014","unstructured":"Knoll BM. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother. 2014;69:3441\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"445_CR23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/cid\/cix198","volume":"64","author":"LL Kovanda","year":"2017","unstructured":"Kovanda LL, Kolamunnage-Dona R, Neely M, Maertens J, Lee M, Hope WW. Pharmacodynamic of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response. Clin Infect Dis. 2017;64:1557\u201363.","journal-title":"Clin Infect Dis"},{"key":"445_CR24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","volume":"101","author":"J Keirns","year":"2017","unstructured":"Keirns J, Desai A, Kowalski D, Lademacher C, Mujais S, Parker B, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101:782\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"445_CR25","unstructured":"Kaindl T, Engelhardt M, Townsend R, et al. Intra-subject variability and exposure-response relationship of isavuconazole in the phase 3 SECURE study in patients with invasive mould disease caused by Aspergillus spp. and other filamentous fungi. Abstract O424. Presented at European Society of Clinical Microbiology and Infectious Diseases (ECCMID) 26th Congress, 9\u201312 April 2016, Amsterdam, Netherlands."},{"key":"445_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12281-017-0287-4","volume":"11","author":"IS Schwartz","year":"2017","unstructured":"Schwartz IS, Wiederhold NP. Update on therapeutic drug monitoring of antifungals for the prophylaxis and treatment of invasive fungal infections. Curr Fungal Infect Rep. 2017;11:75\u201383.","journal-title":"Curr Fungal Infect Rep"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-017-0445-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0445-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0445-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T07:59:34Z","timestamp":1526457574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-017-0445-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,4]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1007\/s13318-017-0445-7","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,4]]}}}